Steroid treatment for relapses in multiple sclerosis - The evidence urges shared decision-making

Acta Neurologica Scandinavica

Volumn 110, Issue 1, 2004, Pages 1-5

  Kopke S ^a,b   Heesen, C ^a   Kasper, J ^a,b   Muhlhauser I ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

Author keywords

Decision making; Drug therapy; Glucocorticoids; Multiple sclerosis; Patient information; Review

Indexed keywords

CORTICOSTEROID; CORTICOTROPIN; METHYLPREDNISOLONE;

ACUTE DISEASE; CORTICOSTEROID THERAPY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DYSPHORIA; EUPHORIA; GASTROINTESTINAL SYMPTOM; HOT FLUSH; HUMAN; INFORMED CONSENT; INSOMNIA; MEDICAL DECISION MAKING; MEDICAL ETHICS; MULTIPLE SCLEROSIS; PRACTICE GUIDELINE; RECURRENCE RISK; RECURRENT DISEASE; RELAPSE; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SIDE EFFECT; STEROID THERAPY;

ADRENAL CORTEX HORMONES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INFORMED CONSENT; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATIENT EDUCATION; PATIENT PARTICIPATION; PRACTICE GUIDELINES; RECURRENCE; RISK; TREATMENT OUTCOME;

EID: 3042744905     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2004.00284.x     Document Type: Review

References (14)

1. LIU C, BLUMHARDT LD. Assessing relapses in treatment trials of relapsing and remitting multiple sclerosis: can we do better? Multiple Sclerosis 1999;5:22-28.
2. GOODIN DS, FROHMAN EM, GARMANY GP et al. Disease modifying therapies in multiple sclerosis. Report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002;58:169-178.
3. Multiple Sklerose Konsensus Gruppe (2002) Immunmodulatorische Stufentherapie der Multiplen Sklerose. Neue Aspekte und praktische Umsetzung, März 2002. Nervenarzt 73:556-563.
4. TREMLETT HL, LUSCOMBE DK, WILES CM. Use of corticosteroids in multiple sclerosis by consultant neurologists in the United Kingdom. J Neurol Neurosurg Psychiatry 1998;65:362-365.
5. CHARLES C, WHELAN T, GAFNI A. What do we mean by partnership in making decisions about treatment? BMJ 1999;319:780-782.
6. General Medical Council. Seeking patients' consent: the ethical considerations. [Article online] http://www.gmc-uk. org/standards/default.htm. Accessed on 29/9/03.
7. FILIPPINI G, BRUSAFERRI F, SIBLEY WA et al . Corticosteroids or ACTH for acute exacerbations in multiple sclerosis (Cochrane Review). In: The Cochrane Library, Issue 3. Oxford: Update Software, 2003.
8. KURTZKE JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983;33:1444-1452.
9. ROTHWELL PM, MCDOWELL Z, WOG CK, DORMAN PJ. Doctors and patients don't agree: cross sectional study of patients' and doctors' perception and assessments of disability in multiple sclerosis. Br Med J 1997;314:1580-1583.
10. SELLEBIERG F, FREDERIKSEN JL, NIELSEN PM et al. Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS. Neurology 1998;51:529-534.
11. KAUFMAN DI, TROBE JD, EGGENBERGER ER et al. Practice parameter: the role of corticosteroids in the management of acute monosymptomatic optic neuritis. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1998;54:2039-2044.
12. BECK RW, CLEARY PA, ANDERSON MM et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 1992;326:581-588.
13. BRUSAFERRI F, CANDELISE L. Steroids for multiple sclerosis and optic neuritis: a meta- analysis of randomized controlled clinical trials. J Neurol 2000;247:435-442.
14. Controlled Trials Register: http://www.controlled-trials.com. Accessed on 29/9/03.